Potentially Inappropriate Opioid Prescribing, Overdose, and Mortality in Massachusetts, 2011–2015
Potentially inappropriate prescribing (PIP) may contribute to opioid overdose.
To examine the association between PIP and adverse events.
Three million seventy-eight thousand thirty-four individuals age ≥ 18, without disseminated cancer, who received prescription opioids between 2011 and 2015.
We defined PIP as (a) morphine equivalent dose ≥ 100 mg/day in ≥ 3 months; (b) overlapping opioid and benzodiazepine prescriptions in ≥ 3 months; (c) ≥ 4 opioid prescribers in any quarter; (d) ≥ 4 opioid-dispensing pharmacies in any quarter; (e) cash purchase of prescription opioids on ≥ 3 occasions; and (f) receipt of opioids in 3 consecutive months without a documented pain diagnosis. We used Cox proportional hazards models to identify PIP practices associated with non-fatal opioid overdose, fatal opioid overdose, and all-cause mortality, controlling for covariates.
All six types of PIP were associated with higher adjusted hazard for all-cause mortality, four of six with non-fatal overdose, and five of six with fatal overdose. Lacking a documented pain diagnosis was associated with non-fatal overdose (adjusted hazard ratio [AHR] 2.21, 95% confidence interval [CI] 2.02–2.41), as was high-dose opioids (AHR 1.68, 95% CI 1.59–1.76). Co-prescription of benzodiazepines was associated with fatal overdose (AHR 4.23, 95% CI 3.85–4.65). High-dose opioids were associated with all-cause mortality (AHR 2.18, 95% CI 2.14–2.23), as was lacking a documented pain diagnosis (AHR 2.05, 95% CI 2.01–2.09). Compared to those who received opioids without PIP, the hazard for fatal opioid overdose with one, two, three, and ≥ four PIP subtypes were 4.24, 7.05, 10.28, and 12.99 (test of linear trend, p < 0.001).
PIP was associated with higher hazard for all-cause mortality, fatal overdose, and non-fatal overdose. Our study implies the possibility of creating a risk score incorporating multiple PIP subtypes, which could be displayed to prescribers in real time.
KEY WORDSpotentially inappropriate prescribing overdose opioids mortality
This study was funded by the GE Foundation (PI: Stopka). The funder had no role in the design, conduct, or reporting of the study.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they do not have a conflict of interest.
The opinions expressed in this manuscript are those of the authors and do not represent the official views or policies of the Massachusetts Department of Public Health or the Commonwealth of Massachusetts.
Responsible Research Statement
Study protocol and statistical code: available from Dr. Rose (email, firstname.lastname@example.org). Dataset: those interested in using the data may contact Dana Bernson (email, email@example.com). All interested parties are encouraged to apply; however, permission to use the data will be prioritized in accordance with current Massachusetts Department of Public Health priorities.
- 19.Commonwealth of Massachusetts: Chapter 55 Website. Accessed at http://www.mass.gov/eohhs/gov/departments/dph/stop-addiction/chapter-55-overdose-assessment.html on May 22, 2018.
- 20.Chapter 55: An Act Requiring Certain Reports for Opiate Overdoses – Initial Report. Accessed at http://www.mass.gov/eohhs/docs/dph/stop-addiction/dph-legislative-report-chapter-55-opioid-overdose-study-9-15-2016.pdf on May 22, 2018.
- 21.Report to the Massachuetts Legislature. “An Assessment of Fatal and Nonfatal Opioid Overdoses in Massachusetts (2011–2015).” Available at: https://www.mass.gov/files/documents/2017/08/31/legislative-report-chapter-55-aug-2017.pdf. Accessed May 22, 2018.
- 24.United States Census Bureau. American FactFinder. Accessed at http://factfinder.census.gov/ on May 22, 2018.
- 29.Massachusetts Medical Society. Smart and safe: information about opioid medications for patients, prescribers, and policymakers. Accessed at http://www.massmed.org/smartandsafe/ on May 22, 2018.
- 31.US Food and Drug Administration. FDA Drug Safety Communication: FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available at: https://www.fda.gov/Drugs/DrugSafety/ucm518473.htm. Accessed May 22, 2018.